Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Bone Biologics Corporation
Market Cap
$878396.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$885939.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
Market Cap
$888387.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
Market Cap
$787624.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
Market Cap
$1.02M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
Market Cap
$1.14M
EBITDA Margin
-6.76%
TTM Avg
-0.42%
3Y Avg
7.09%
5Y Avg
7.09%
Market Cap
$1.17M
EBITDA Margin
-17.60%
TTM Avg
-16.25%
3Y Avg
-23.94%
5Y Avg
-32.10%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bone Biologics Corporation (BBLG) | $878396.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| CDT Equity Inc. (CDT)vs › | $707297.00 | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -6.76% | -0.42% | 7.09% | 7.09% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | -17.60% | -16.25% | -23.94% | -32.10% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.17M | -40873.19% | -40873.19% | -21172.28% | -10780.34% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
